V1C

V1C is an experimental **modified netrin-1-derived peptide** being studied preclinically for **pulmonary hypertension**. It is a cyclized version of the original V1 netrin-1 peptide, designed to improve peptide stability and resistance to oxidative degradation relative to the native sequence. Based on the provided publication, V1C is intended to engage the **Deleted in Colorectal Carcinoma receptor** signaling axis used by netrin-1, leading to restoration of endothelial nitric oxide synthase coupling, improved nitric oxide bioavailability, reduced reactive oxygen species generation, and attenuation of pulmonary vascular remodeling and right heart hypertrophy in hypoxia-exposed mice. The program appears to be an academic, preclinical peptide therapeutic effort rather than a commercialized drug, with no evidence in the provided material of clinical development, branding, or approved manufacturing.

Other names

cyclized netrin-1-derived peptide V1Cmodified netrin-1-derived small peptide V1C